INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer—Toxicity Update on First 213 Patients.

Authors

P. Singh, Mayo Clinic, Arizona, Phoenix, AZ
J.A. Efstathiou, Massachusetts General Hospital, Boston, MA
M. Plets, Fred Hutchinson Cancer Research Center, Seattle, WA
S.G. Jhavar, Baylor Scott & White Health, Temple, TX
S. Delacroix, LSU Health Sciences Center - New OrleansFollow
A. Tripathi, University of Oklahoma
A. Gupta, Cedars Sinai Medical Center, Los Angeles, CA
S. Sachdev, Northwestern University
A. Jani, Emory University
A.N. Kirschner, Vanderbilt University Medical Center
C. Tangen, Fred Hutchinson Cancer Research Center, Seattle, WA
R. Bangs, Bladder Cancer Advocacy Network, Pittsford, NY
M. Joshi, Penn State Cancer Institute, Hershey, PA
B.A. Costello, Mayo Clinic, Rochester, MN
I.L. Thompson, Texas Urology Group, San Antonio, TX
F.Y. Feng, University of California San Francisco
S. Lerner, Baylor College of Medicine

Document Type

Conference Proceeding

Publication Date

10-22-2022

Publication Title

International Journal of Radiation Oncology, Biology, Physics

Abstract

ASTRO Annual 2022 Meeting

First Page

S76

Last Page

S77

Volume

114

Issue

3, Supplement 1

Comments

Abstract Number: 237

Recommended Citation

Singh, P.; Efstathiou, J.A.; Plets, M.; Jhavar, S.G.; Delacroix, S.; Tripathi, A.; Gupta, A.; Sachdev, S.; Jani, A.; Kirschner, A.N.; Tangen, C.; Bangs, R.; Joshi, M.; Costello, B.A.; Thompson, I.L.; Feng, F.Y.; and Lerner, S., "INTACT (S/N1806): Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer—Toxicity Update on First 213 Patients." (2022). School of Medicine Faculty Publications. 909.
https://digitalscholar.lsuhsc.edu/som_facpubs/909
10.1016/j.ijrobp.2022.07.475